Ocular Surface最新文献

英文中文

Downregulation of the core circadian gene Nr1d2 in the lacrimal gland contributes to postoperative dry eye disease by impairing lipid metabolism 泪腺核心昼夜节律基因Nr1d2的下调通过损害脂质代谢参与术后干眼病

IF 5.6 1区医学 Q1 OPHTHALMOLOGY

Ocular Surface

Pub Date : 2025-10-01 Epub Date: 2025-08-28 DOI: 10.1016/j.jtos.2025.08.009

Shiji Liu , Yuke Huang , Xi Chen , Huanhuan Ren, Jiaxin Chen, Qingqing Mu, Jiejie Zhuang, Yan Li, Jin Qiu, Keming Yu, Jing Zhuang

Purpose

Dry eye disease (DED) is a prevalent complication after refractive surgery, and its underlying mechanisms are not fully understood. Given that circadian rhythm tightly regulates tear secretion, this study aims to investigate the circadian changes in the lacrimal gland after corneal refractive surgery and the associated mechanisms.

Methods

C57/BL6 mice underwent corneal epithelial abrasion and stromal severing. DED was assessed using phenol red thread and fluorescein staining. RNA sequencing identified differentially expressed genes (DEGs) related to circadian rhythm, validated by RT-qPCR and Western blotting. Immunofluorescence, TUNEL staining, untargeted metabolomics, Oil-Red-O staining, and TEM were performed to analyze the lacrimal gland changes. Clinically, DED symptoms were evaluated using the OSDI questionnaire in 867 post-surgical patients and 705 controls.

Results

Corneal epithelial abrasion and stromal severing induced DED symptoms and lacrimal dysfunction, including reduced tear volume, ocular surface inflammation, and lacrimal pathophysiological changes. Nr1d2, the key circadian rhythm gene, was significantly down-regulated in the lacrimal gland compared to the control. Activation of Nr1d2 with SR9011 restored the lacrimal gland function and alleviated DED symptoms. Furthermore, the down-regulation of Nr1d2 significantly impaired lipid metabolism and mitochondrial function in the lacrimal gland, which SR9011 reversed. Clinically, the incidence of DED was markedly higher in the surgical cohort, with symptom occurrence exhibiting diurnal variation and peaking in the early morning and late evening.

Conclusions

Disruption of circadian rhythms, specifically Nr1d2 downregulation, contributes to post-surgical DED. Targeting Nr1d2 may offer a novel therapeutic approach to restore lacrimal gland function and alleviate DED.

目的：干眼病是屈光手术后常见的并发症，其发病机制尚不完全清楚。鉴于昼夜节律紧密调控泪液分泌，本研究旨在探讨角膜屈光手术后泪腺的昼夜节律变化及其机制。方法：对C57/BL6小鼠进行角膜上皮磨损和间质切断。采用酚红线和荧光素染色评价DED。RNA测序鉴定出与昼夜节律相关的差异表达基因（DEGs），并通过RT-qPCR和Western blotting验证。采用免疫荧光、TUNEL染色、非靶向代谢组学、Oil-Red-O染色和透射电镜分析泪腺的变化。临床应用OSDI问卷对867例术后患者和705例对照患者进行DED症状评估。结果：角膜上皮磨损和间质损伤引起DED症状和泪液功能障碍，包括泪液量减少、眼表炎症和泪液病理生理改变。与对照组相比，关键的昼夜节律基因Nr1d2在泪腺中显著下调。SR9011激活Nr1d2恢复泪腺功能，缓解DED症状。此外，Nr1d2的下调显著损害了泪腺的脂质代谢和线粒体功能，SR9011逆转了这一变化。临床上，手术组DED的发生率明显较高，且症状呈现昼夜变化，在清晨和傍晚达到高峰。结论：昼夜节律的破坏，特别是Nr1d2的下调，有助于术后DED。靶向Nr1d2可能为恢复泪腺功能和缓解DED提供新的治疗途径。

{"title":"Downregulation of the core circadian gene Nr1d2 in the lacrimal gland contributes to postoperative dry eye disease by impairing lipid metabolism","authors":"Shiji Liu , Yuke Huang , Xi Chen , Huanhuan Ren, Jiaxin Chen, Qingqing Mu, Jiejie Zhuang, Yan Li, Jin Qiu, Keming Yu, Jing Zhuang","doi":"10.1016/j.jtos.2025.08.009","DOIUrl":"10.1016/j.jtos.2025.08.009","url":null,"abstract":"<div><h3>Purpose</h3><div>Dry eye disease (DED) is a prevalent complication after refractive surgery, and its underlying mechanisms are not fully understood. Given that circadian rhythm tightly regulates tear secretion, this study aims to investigate the circadian changes in the lacrimal gland after corneal refractive surgery and the associated mechanisms.</div></div><div><h3>Methods</h3><div>C57/BL6 mice underwent corneal epithelial abrasion and stromal severing. DED was assessed using phenol red thread and fluorescein staining. RNA sequencing identified differentially expressed genes (DEGs) related to circadian rhythm, validated by RT-qPCR and Western blotting. Immunofluorescence, TUNEL staining, untargeted metabolomics, Oil-Red-O staining, and TEM were performed to analyze the lacrimal gland changes. Clinically, DED symptoms were evaluated using the OSDI questionnaire in 867 post-surgical patients and 705 controls.</div></div><div><h3>Results</h3><div>Corneal epithelial abrasion and stromal severing induced DED symptoms and lacrimal dysfunction, including reduced tear volume, ocular surface inflammation, and lacrimal pathophysiological changes. Nr1d2, the key circadian rhythm gene, was significantly down-regulated in the lacrimal gland compared to the control. Activation of Nr1d2 with SR9011 restored the lacrimal gland function and alleviated DED symptoms. Furthermore, the down-regulation of Nr1d2 significantly impaired lipid metabolism and mitochondrial function in the lacrimal gland, which SR9011 reversed. Clinically, the incidence of DED was markedly higher in the surgical cohort, with symptom occurrence exhibiting diurnal variation and peaking in the early morning and late evening.</div></div><div><h3>Conclusions</h3><div>Disruption of circadian rhythms, specifically Nr1d2 downregulation, contributes to post-surgical DED. Targeting Nr1d2 may offer a novel therapeutic approach to restore lacrimal gland function and alleviate DED.</div></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 290-301"},"PeriodicalIF":5.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ocular surface epithelial immune cells and corneal nerves in dry eye disease - A systematic review and meta-analysis of in vivo confocal microscopy data 干眼病的眼表上皮免疫细胞和角膜神经-体内共聚焦显微镜数据的系统回顾和荟萃分析

IF 5.9 1区医学 Q1 OPHTHALMOLOGY

Ocular Surface

Pub Date : 2025-10-01 Epub Date: 2025-06-20 DOI: 10.1016/j.jtos.2025.06.005

Soumen Sadhu , Isabelle Jalbert , Luz Palacios-Derflingher , Ali Alghamdi , Blanka Golebiowski , Fiona Stapleton

Purpose

To examine ocular surface epithelial immune cell (EIC) density and corneal nerve parameters between patients with dry eye disease (DED) compared to healthy controls with further comparisons between auto-immune - Sjӧgren Syndrome DED (SS-DED) and non-autoimmune – non-Sjӧgren Syndrome DED (NSS-DED) subtypes.

Methods

A systematic review and meta-analysis following PRISMA guidelines (Prospero-CRD42023446763) were conducted including studies reporting corneal and conjunctival EIC density and/or corneal nerve parameters in DED and healthy controls using in vivo confocal microscopy. Electronic databases – PubMed, Embase, Scopus, Web of Science were searched from inception to March 2025.

Results

The meta-analysis included 24 studies (n = 1060 DED, n = 521 controls) reporting EIC density, 30 studies reporting nerve length (CNL; n = 1450 DED, n = 643 controls) and 20 studies reporting nerve density (CND; n = 919 DED, n = 462 controls) in the central cornea. Studies of other ocular surface locations were insufficient for meta-analysis. Higher central corneal EIC density was evident in DED compared to controls (MD: 57.9 cells/mm²; 95 % CI: 43.3, 72.5; p < 0.001), and in, SS-DED compared to NSS-DED (51.0 cells/mm²; 95 % CI: 12.0, 90.0; p = 0.01). DED had lower CNL (−4.0 mm/mm²; 95 % CI: 5.2, −2.7; p < 0.001) and CND (−7.2 nerves/mm²; 95 % CI: 10.3, −4.1; p < 0.001) compared to controls. No significant differences in nerve parameters were found between SS-DED and NSS-DED subtypes (CNL: 95 % CI: 3.0, 1.4, CND: 6.8, 4.8; p ≥ 0.46).

Conclusion

DED involves substantial EIC infiltration and reduced corneal nerve parameters. SS-DED is distinguished by higher EIC density than NSS-DED, while no differences were observed in corneal nerve parameters.

研究干眼病（DED）患者与健康对照组相比眼表面上皮免疫细胞（EIC）密度和角膜神经参数，并进一步比较自身免疫-Sjӧgren综合征DED （SS-DED）和非自身免疫- non-Sjӧgren综合征DED （NSS-DED）亚型之间的差异。

{"title":"Ocular surface epithelial immune cells and corneal nerves in dry eye disease - A systematic review and meta-analysis of in vivo confocal microscopy data","authors":"Soumen Sadhu , Isabelle Jalbert , Luz Palacios-Derflingher , Ali Alghamdi , Blanka Golebiowski , Fiona Stapleton","doi":"10.1016/j.jtos.2025.06.005","DOIUrl":"10.1016/j.jtos.2025.06.005","url":null,"abstract":"<div><h3>Purpose</h3><div>To examine ocular surface epithelial immune cell (EIC) density and corneal nerve parameters between patients with dry eye disease (DED) compared to healthy controls with further comparisons between auto-immune - Sjӧgren Syndrome DED (SS-DED) and non-autoimmune – non-Sjӧgren Syndrome DED (NSS-DED) subtypes.</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis following PRISMA guidelines (Prospero-CRD42023446763) were conducted including studies reporting corneal and conjunctival EIC density and/or corneal nerve parameters in DED and healthy controls using <em>in vivo</em> confocal microscopy. Electronic databases – PubMed, Embase, Scopus, Web of Science were searched from inception to March 2025.</div></div><div><h3>Results</h3><div>The meta-analysis included 24 studies (n = 1060 DED, n = 521 controls) reporting EIC density, 30 studies reporting nerve length (CNL; n = 1450 DED, n = 643 controls) and 20 studies reporting nerve density (CND; n = 919 DED, n = 462 controls) in the central cornea. Studies of other ocular surface locations were insufficient for meta-analysis. Higher central corneal EIC density was evident in DED compared to controls (MD: 57.9 cells/mm<sup>2</sup>; 95 % CI: 43.3, 72.5; p < 0.001), and in, SS-DED compared to NSS-DED (51.0 cells/mm<sup>2</sup>; 95 % CI: 12.0, 90.0; p = 0.01). DED had lower CNL (−4.0 mm/mm<sup>2</sup>; 95 % CI: 5.2, −2.7; p < 0.001) and CND (−7.2 nerves/mm<sup>2</sup>; 95 % CI: 10.3, −4.1; p < 0.001) compared to controls. No significant differences in nerve parameters were found between SS-DED and NSS-DED subtypes (CNL: 95 % CI: 3.0, 1.4, CND: 6.8, 4.8; p ≥ 0.46).</div></div><div><h3>Conclusion</h3><div>DED involves substantial EIC infiltration and reduced corneal nerve parameters. SS-DED is distinguished by higher EIC density than NSS-DED, while no differences were observed in corneal nerve parameters.</div></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 80-96"},"PeriodicalIF":5.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Models for Meibomian gland dysfunction: In vivo and in vitro”, Review article [Ocul. Surf. 32 (2024) 154–165] “睑板腺功能障碍模型：体内和体外”的勘误表。综述文章，眼表32(2024)154-165。

IF 5.9 1区医学 Q1 OPHTHALMOLOGY

Ocular Surface

Pub Date : 2025-10-01 Epub Date: 2025-06-23 DOI: 10.1016/j.jtos.2025.06.009

Jinghua Bu , Yuli Guo , Yang Wu , Rongrong Zhang , Jingbin Zhuang , Jiankai Zhao , Le Sun , Andrew J. Quantock , Zuguo Liu , Wei Li

引用次数: 0

MicroRNAs in corneal Diseases: Emerging roles as biomarkers, regulators, and therapeutics microrna在角膜疾病中的作用：生物标志物、调节因子和治疗方法。

IF 5.9 1区医学 Q1 OPHTHALMOLOGY

Ocular Surface

Pub Date : 2025-10-01 Epub Date: 2025-05-22 DOI: 10.1016/j.jtos.2025.05.007

Liangbo Chen , Shiding Li , Yao Fu

MicroRNAs (miRNAs) are conserved, short, non-coding RNAs that play a crucial role in regulating gene expression. Emerging evidence suggests that miRNAs are closely involved in the pathophysiology of various corneal diseases, particularly in regulating corneal wound healing, inflammation and neovascularization. In this review, we summarized the recent progress of miRNAs in corneal diseases, especially focused on their application as diagnostic biomarkers, regulators of cell biology, and therapeutic targets. Recent advances in miRNA detection technology have made it possible to analyze minimal miRNAs in samples such as tears or exosomes, further enhancing the ability to identify disease-specific miRNA profiles and providing potential objective indicators for the early diagnosis of disease. Meanwhile, we summarized the mechanisms and pathways of multiple miRNAs in regulating various biological processes of corneal cells, as well as the advantages of studying miRNA compared to proteins or genes. Furthermore, we explore the potential of miRNAs-based therapies, especially introduce various miRNA delivery systems and challenges associated with clinical translation. This review highlights the need for further research to harness the full potential of miRNAs in treating various corneal diseases.

MicroRNAs （miRNAs）是一种保守的、短的非编码rna，在调节基因表达中起着至关重要的作用。越来越多的证据表明，mirna密切参与各种角膜疾病的病理生理，特别是在调节角膜伤口愈合、炎症和新生血管方面。本文综述了近年来mirna在角膜疾病中的研究进展，重点介绍了其在角膜疾病诊断标志物、细胞生物学调节因子和治疗靶点等方面的应用。miRNA检测技术的最新进展使得分析眼泪或外泌体等样品中的最小miRNA成为可能，进一步增强了识别疾病特异性miRNA谱的能力，并为疾病的早期诊断提供了潜在的客观指标。同时，我们总结了多种miRNA调控角膜细胞各种生物过程的机制和途径，以及研究miRNA相对于蛋白质或基因的优势。此外，我们探索了基于miRNA的治疗的潜力，特别是介绍了各种miRNA传递系统和与临床转化相关的挑战。这篇综述强调了需要进一步研究以充分利用mirna在治疗各种角膜疾病中的潜力。

{"title":"MicroRNAs in corneal Diseases: Emerging roles as biomarkers, regulators, and therapeutics","authors":"Liangbo Chen , Shiding Li , Yao Fu","doi":"10.1016/j.jtos.2025.05.007","DOIUrl":"10.1016/j.jtos.2025.05.007","url":null,"abstract":"<div><div>MicroRNAs (miRNAs) are conserved, short, non-coding RNAs that play a crucial role in regulating gene expression. Emerging evidence suggests that miRNAs are closely involved in the pathophysiology of various corneal diseases, particularly in regulating corneal wound healing, inflammation and neovascularization. In this review, we summarized the recent progress of miRNAs in corneal diseases, especially focused on their application as diagnostic biomarkers, regulators of cell biology, and therapeutic targets. Recent advances in miRNA detection technology have made it possible to analyze minimal miRNAs in samples such as tears or exosomes, further enhancing the ability to identify disease-specific miRNA profiles and providing potential objective indicators for the early diagnosis of disease. Meanwhile, we summarized the mechanisms and pathways of multiple miRNAs in regulating various biological processes of corneal cells, as well as the advantages of studying miRNA compared to proteins or genes. Furthermore, we explore the potential of miRNAs-based therapies, especially introduce various miRNA delivery systems and challenges associated with clinical translation. This review highlights the need for further research to harness the full potential of miRNAs in treating various corneal diseases.</div></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 14-30"},"PeriodicalIF":5.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety of subconjunctival injection of mesenchymal stromal cells in persistent corneal epithelial disease – A phase 1b clinical trial 结膜下注射间充质间质细胞治疗持续性角膜上皮疾病的安全性- 1b期临床试验

IF 5.9 1区医学 Q1 OPHTHALMOLOGY

Ocular Surface

Pub Date : 2025-10-01 Epub Date: 2025-05-23 DOI: 10.1016/j.jtos.2025.05.009

Grace C. Tu , Farshad Abedi , Arthur Y. Chang , Xiang Shen , Mohammad Soleimani , Iskra Araujo , Rebecca Jung , Jeonghyun Kwon , Khandeker N. Anwar , Zohreh Arabpour , Nadim Mahmud , Elmer Y. Tu , Reza Dana , Peiman Hematti , Charlotte E. Joslin , Ali R. Djalilian

Purpose

To investigate the safety and tolerability of subconjunctival injection of three escalating doses of allogeneic bone marrow-derived mesenchymal stromal cells (MSCs) in patients with persistent corneal epithelial defect/disease (PCED).

Design

Prospective single-center open label phase 1b clinical trial.

Participants

Patients with PCED in the setting of neurotrophic keratitis and/or limbal stem cell deficiency.

Methods

A dose escalation study design was used. The first three patients received a subconjunctival injection of 1 × 10⁶ MSCs/50 μL suspension; subsequently, three participants were treated with 1 subconjunctival injection of 3 × 10⁶ MSCs/150 μL; and two participants received 2 subconjunctival injections of 3 × 10⁶ MSCs/150 μl in 2 conjunctival sites.

Main outcome measures

The primary outcome was the safety of the treatment determined on day 28 post-injection. Ocular surface toxicity and other ocular or systemic treatment emergent adverse events (TEAEs) were assessed at 1, 7, 14, 28 and 90 days. Demonstration of safety on day 28 was required before escalating to the next higher dose. Changes in the PCED were also monitored.

Results

Eight participants completed the 90-day study. All 3 doses of subconjunctival MSCs were well tolerated. No participant developed ocular surface toxicity or other ocular or systemic TEAEs. The size of the PCED improved in 5 (63 %) patients; it increased in 2 (25 %) patients; and no progressive improvement was observed with dose escalation.

Conclusion

Subconjunctival administration of MSCs was safe and well tolerated with no systemic or ocular toxicity in patients with PCED. Improvement in epithelial defect size was observed in 63 % of the participants.

目的：探讨三种递增剂量的同种异体骨髓间充质间质细胞（MSCs）在持续性角膜上皮缺损/疾病（PCED）患者结膜下注射的安全性和耐受性。设计：前瞻性单中心开放标签1b期临床试验。参与者：神经营养性角膜炎和/或角膜缘干细胞缺乏的PCED患者。方法：采用剂量递增研究设计。前3例患者在结膜下注射1 × 106个MSCs/50 μL悬液；随后，3名受试者接受1次结膜下注射3 × 106个MSCs/150 μL；2例患者在2个结膜部位注射3 × 106个MSCs/150μl。主要观察指标：主要观察指标为注射后第28天确定的治疗安全性。在第1、7、14、28和90天评估眼表毒性和其他眼部或全身治疗紧急不良事件（teae）。需要在第28天进行安全性证明，然后再进行下一个更高的剂量。还监测了PCED的变化。结果：8名参与者完成了为期90天的研究。所有3种剂量的结膜下MSCs均耐受良好。没有参与者发生眼表毒性或其他眼部或全身teae。5例（63%）患者PCED大小改善；2例（25%）患者升高；随着剂量的增加，没有观察到进行性改善。结论：在PCED患者中，结膜下给药MSCs是安全且耐受性良好的，无全身或眼部毒性。在63%的参与者中观察到上皮缺陷大小的改善。

{"title":"Safety of subconjunctival injection of mesenchymal stromal cells in persistent corneal epithelial disease – A phase 1b clinical trial","authors":"Grace C. Tu , Farshad Abedi , Arthur Y. Chang , Xiang Shen , Mohammad Soleimani , Iskra Araujo , Rebecca Jung , Jeonghyun Kwon , Khandeker N. Anwar , Zohreh Arabpour , Nadim Mahmud , Elmer Y. Tu , Reza Dana , Peiman Hematti , Charlotte E. Joslin , Ali R. Djalilian","doi":"10.1016/j.jtos.2025.05.009","DOIUrl":"10.1016/j.jtos.2025.05.009","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the safety and tolerability of subconjunctival injection of three escalating doses of allogeneic bone marrow-derived mesenchymal stromal cells (MSCs) in patients with persistent corneal epithelial defect/disease (PCED).</div></div><div><h3>Design</h3><div>Prospective single-center open label phase 1b clinical trial.</div></div><div><h3>Participants</h3><div>Patients with PCED in the setting of neurotrophic keratitis and/or limbal stem cell deficiency.</div></div><div><h3>Methods</h3><div>A dose escalation study design was used. The first three patients received a subconjunctival injection of 1 × 10<sup>6</sup> MSCs/50 μL suspension; subsequently, three participants were treated with 1 subconjunctival injection of 3 × 10<sup>6</sup> MSCs/150 μL; and two participants received 2 subconjunctival injections of 3 × 10<sup>6</sup> MSCs/150 μl in 2 conjunctival sites.</div></div><div><h3>Main outcome measures</h3><div>The primary outcome was the safety of the treatment determined on day 28 post-injection. Ocular surface toxicity and other ocular or systemic treatment emergent adverse events (TEAEs) were assessed at 1, 7, 14, 28 and 90 days. Demonstration of safety on day 28 was required before escalating to the next higher dose. Changes in the PCED were also monitored.</div></div><div><h3>Results</h3><div>Eight participants completed the 90-day study. All 3 doses of subconjunctival MSCs were well tolerated. No participant developed ocular surface toxicity or other ocular or systemic TEAEs. The size of the PCED improved in 5 (63 %) patients; it increased in 2 (25 %) patients; and no progressive improvement was observed with dose escalation.</div></div><div><h3>Conclusion</h3><div>Subconjunctival administration of MSCs was safe and well tolerated with no systemic or ocular toxicity in patients with PCED. Improvement in epithelial defect size was observed in 63 % of the participants.</div></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 8-13"},"PeriodicalIF":5.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Re: Reply to Prof. Jacqueline Tan's letter. Efficacy of eyelid warming devices as a first-step treatment in meibomian gland dysfunction: A systematic review with meta-analysis. 2025; 37:33-46 眼睑温热装置作为睑板腺功能障碍第一步治疗的疗效：一项系统综述和meta分析。

IF 5.6 1区医学 Q1 OPHTHALMOLOGY

Ocular Surface

Pub Date : 2025-10-01 Epub Date: 2025-04-17 DOI: 10.1016/j.jtos.2025.04.002

Ballesteros-Sánchez Antonio, Carlos Rocha-de-Lossada, José-María Sánchez-González

引用次数: 0

Ocular manifestations in Stevens‒Johnson syndrome/toxic epidermal necrolysis in cancer patients Stevens-Johnson综合征/肿瘤患者中毒性表皮坏死松解的眼部表现

IF 5.6 1区医学 Q1 OPHTHALMOLOGY

Ocular Surface

Pub Date : 2025-10-01 Epub Date: 2025-10-27 DOI: 10.1016/j.jtos.2025.10.010

Jin-Jhe Wang , Chun-Bing Chen , Eugene Yu-Chuan Kang , Wen-Hung Chung , John Wen-Cheng Chang , Kevin Sheng-Kai Ma , Yueh-Ju Tsai , Ming-Tse Kuo , Chi-Chin Sun , Hung-Chi Chen , Shin-Yi Chen , Kuo-Hsuan Hung , Hsin-Yuan Tan , Pier Luigi Surico , David Hui-Kang Ma

Purpose

To evaluate the characteristics, risk factors, and outcomes of ocular involvement in cancer patients with Stevens‒Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), focusing on the role of immune checkpoint inhibitors (ICIs).

Methods

This retrospective case‒control study was conducted at Chang Gung Memorial Hospital, Linkou, Taiwan, between 2004 and 2024. A total of 112 patients with confirmed SJS/TEN and concurrent malignancies were included. The primary outcomes were the prevalence and severity of acute and chronic ocular involvement, assessed using Sotozono's classification. Risk factors for ocular involvement were investigated through univariate and multivariate logistic regression.

Results

Of 112 patients, 46 (41.1 %) developed ocular complications. TEN (adjusted OR, 3.11; 95 % CI, 1.24–7.78; P = 0.02), systemic mucosal involvement (adjusted OR, 4.89; 95 % CI, 1.52–15.80; P = 0.01), and polypharmacy (adjusted OR, 3.52; 95 % CI, 1.36–9.11; P = 0.01) were significant risk factors for ocular involvement. ICI-related SJS/TEN exhibited longer latency (31.0 vs. 13.4 days; P < 0.001) and delayed healing (72.3 vs. 45.8 days; P = 0.002). Chronic ocular complications were more severe in surviving ICI-related patients, as indicated by significantly higher chronic Sotozono scores (7.5 vs. 3.7; P = 0.001), worse dry eye (Schirmer's test 1.8 vs. 3.4 mm; P = 0.01), and poorer visual recovery (0.11 vs. 0.43 logMAR; P = 0.001).

Conclusions

SJS/TEN in cancer patients, particularly those receiving ICIs, is associated with substantial ocular morbidity. The increasing prevalence of ICI-related SJS/TEN emphasizes the need for vigilant ophthalmologic intervention and long-term monitoring.

目的探讨Stevens-Johnson综合征/中毒性表皮坏死松解（SJS/TEN）患者眼部受损伤的特点、危险因素及预后，重点探讨免疫检查点抑制剂（ICIs）的作用。方法回顾性病例对照研究于2004 ~ 2024年在台湾省林口市长庚纪念医院进行。共纳入112例确诊为SJS/TEN并伴有恶性肿瘤的患者。主要结果是急性和慢性眼部受累的患病率和严重程度，使用Sotozono分类进行评估。通过单因素和多因素logistic回归研究眼部受累的危险因素。结果112例患者中有46例（41.1%）出现眼部并发症。TEN（校正OR， 3.11; 95% CI, 1.24-7.78; P = 0.02）、全身粘膜受累（校正OR， 4.89; 95% CI, 1.52-15.80; P = 0.01）和多药（校正OR， 3.52; 95% CI, 1.36-9.11; P = 0.01）是眼部受累的显著危险因素。ici相关的SJS/TEN表现出更长的潜伏期（31.0 vs. 13.4天；P < 0.001）和延迟的愈合（72.3 vs. 45.8天；P = 0.002）。存活的ici相关患者的慢性眼部并发症更为严重，慢性Sotozono评分显著较高（7.5比3.7,P = 0.001），干眼更严重（Schirmer's test 1.8比3.4 mm, P = 0.01），视力恢复较差（0.11比0.43 logMAR, P = 0.001）。结论ssjs /TEN在癌症患者，特别是接受ICIs的患者中，与大量眼部发病率相关。ici相关SJS/TEN患病率的增加强调了警惕的眼科干预和长期监测的必要性。

{"title":"Ocular manifestations in Stevens‒Johnson syndrome/toxic epidermal necrolysis in cancer patients","authors":"Jin-Jhe Wang , Chun-Bing Chen , Eugene Yu-Chuan Kang , Wen-Hung Chung , John Wen-Cheng Chang , Kevin Sheng-Kai Ma , Yueh-Ju Tsai , Ming-Tse Kuo , Chi-Chin Sun , Hung-Chi Chen , Shin-Yi Chen , Kuo-Hsuan Hung , Hsin-Yuan Tan , Pier Luigi Surico , David Hui-Kang Ma","doi":"10.1016/j.jtos.2025.10.010","DOIUrl":"10.1016/j.jtos.2025.10.010","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the characteristics, risk factors, and outcomes of ocular involvement in cancer patients with Stevens‒Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), focusing on the role of immune checkpoint inhibitors (ICIs).</div></div><div><h3>Methods</h3><div>This retrospective case‒control study was conducted at Chang Gung Memorial Hospital, Linkou, Taiwan, between 2004 and 2024. A total of 112 patients with confirmed SJS/TEN and concurrent malignancies were included. The primary outcomes were the prevalence and severity of acute and chronic ocular involvement, assessed using Sotozono's classification. Risk factors for ocular involvement were investigated through univariate and multivariate logistic regression.</div></div><div><h3>Results</h3><div>Of 112 patients, 46 (41.1 %) developed ocular complications. TEN (adjusted OR, 3.11; 95 % CI, 1.24–7.78; P = 0.02), systemic mucosal involvement (adjusted OR, 4.89; 95 % CI, 1.52–15.80; P = 0.01), and polypharmacy (adjusted OR, 3.52; 95 % CI, 1.36–9.11; P = 0.01) were significant risk factors for ocular involvement. ICI-related SJS/TEN exhibited longer latency (31.0 vs. 13.4 days; P < 0.001) and delayed healing (72.3 vs. 45.8 days; P = 0.002). Chronic ocular complications were more severe in surviving ICI-related patients, as indicated by significantly higher chronic Sotozono scores (7.5 vs. 3.7; P = 0.001), worse dry eye (Schirmer's test 1.8 vs. 3.4 mm; P = 0.01), and poorer visual recovery (0.11 vs. 0.43 logMAR; P = 0.001).</div></div><div><h3>Conclusions</h3><div>SJS/TEN in cancer patients, particularly those receiving ICIs, is associated with substantial ocular morbidity. The increasing prevalence of ICI-related SJS/TEN emphasizes the need for vigilant ophthalmologic intervention and long-term monitoring.</div></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 367-376"},"PeriodicalIF":5.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145382680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pipeline: Patient, physician and developer view of drugs vs. devices 管道：患者、医生和开发人员对药物与设备的看法

IF 5.6 1区医学 Q1 OPHTHALMOLOGY

Ocular Surface

Pub Date : 2025-10-01 Epub Date: 2025-08-18 DOI: 10.1016/j.jtos.2025.08.004

Gary D. Novack

引用次数: 0

Heightened visual light sensitivity discomfort measured by the ocular photosensitivity analyzer is associated with chronic ocular pain 眼光敏度分析仪测量的视光敏度升高的不适与慢性眼痛有关

IF 5.9 1区医学 Q1 OPHTHALMOLOGY

Ocular Surface

Pub Date : 2025-10-01 Epub Date: 2025-06-19 DOI: 10.1016/j.jtos.2025.06.007

Ema V. Karakoleva , Nicholas Pondelis , Cameron Talbert , Mariela C. Aguilar , Alex Gonzalez , Cornelis Rowaan , Heather Durkee , Paula A. Sepulveda-Beltran , David Valdes-Arias , Chloe Shields , Shreya Bhatt , David Zurakowski , Deborah S. Jacobs , Joseph B. Ciolino , Elizabeth R. Felix , Jean-Marie Parel , Eric A. Moulton , Anat Galor

Purpose

To quantify visual photosensitivity discomfort thresholds (VPDT) in individuals with chronic ocular pain (COP) compared to controls without COP and explore relationships between VPDT, demographics, clinical factors, and ocular metrics.

Methods

Prospective case-control study of 75 participants: 36 with COP (age 46.5 ± 15.6 years; 56 % female) and 39 controls (39.2 ± 15.6 years; 56 % female). COP was defined by self-reported ocular pain intensity ≥15 on a numerical rating scale (range, 0–100) for ≥3 months. COP cases were subclassified into inflammatory (Sjögren's disease) and neuropathic ocular pain subgroups. VPDT was measured using the Ocular Photosensitivity Analyzer (OPA), and ocular symptoms were assessed using the Visual Light Sensitivity Questionnaire (VLSQ-8; 8–40) and Ocular Surface Disease Index (OSDI; 0–100), with OSDI Question 1 addressing light sensitivity (OSDI-Q1; 0–4).

Results

COP patients exhibited lower VPDT than controls (log lux, 1.60 ± 1.17 vs. 2.42 ± 1.05; P = 0.006), indicating greater photosensitivity discomfort. No differences in VPDT were seen across COP subtypes. COP patients also reported greater symptom severity than controls, with higher VLSQ-8 (21.92 ± 1.41 vs. 9.03 ± 0.53), OSDI (50.84 ± 3.88 vs. 2.82 ± 0.85), and OSDI-Q1 (2.00 ± 0.24 vs. 0.14 ± 0.06) scores (all P < 0.001). VPDT negatively correlated with VLSQ-8 (ρ = −0.75) and OSDI-Q1 (ρ = −0.62), demonstrating alignment between subjective light sensitivity symptoms and OPA-measured photosensitivity discomfort. Multivariable regression identified fibromyalgia as the strongest predictor of VPDT (19.6 % variance explained), with chronic fatigue improving the model (26.5 %).

Conclusion

COP subjects display greater photosensitivity-related discomfort than controls, highlighting the OPA's potential as a psychophysical tool for quantifying photoallodynia. Further research is needed to assess its diagnostic utility across COP subtypes.

量化慢性眼痛（COP）患者的视觉光敏性不适阈值（VPDT），并与无COP的对照组进行比较，探讨VPDT、人口统计学、临床因素和眼部指标之间的关系。

{"title":"Heightened visual light sensitivity discomfort measured by the ocular photosensitivity analyzer is associated with chronic ocular pain","authors":"Ema V. Karakoleva , Nicholas Pondelis , Cameron Talbert , Mariela C. Aguilar , Alex Gonzalez , Cornelis Rowaan , Heather Durkee , Paula A. Sepulveda-Beltran , David Valdes-Arias , Chloe Shields , Shreya Bhatt , David Zurakowski , Deborah S. Jacobs , Joseph B. Ciolino , Elizabeth R. Felix , Jean-Marie Parel , Eric A. Moulton , Anat Galor","doi":"10.1016/j.jtos.2025.06.007","DOIUrl":"10.1016/j.jtos.2025.06.007","url":null,"abstract":"<div><h3>Purpose</h3><div>To quantify visual photosensitivity discomfort thresholds (VPDT) in individuals with chronic ocular pain (COP) compared to controls without COP and explore relationships between VPDT, demographics, clinical factors, and ocular metrics.</div></div><div><h3>Methods</h3><div>Prospective case-control study of 75 participants: 36 with COP (age 46.5 ± 15.6 years; 56 % female) and 39 controls (39.2 ± 15.6 years; 56 % female). COP was defined by self-reported ocular pain intensity ≥15 on a numerical rating scale (range, 0–100) for ≥3 months. COP cases were subclassified into inflammatory (Sjögren's disease) and neuropathic ocular pain subgroups. VPDT was measured using the Ocular Photosensitivity Analyzer (OPA), and ocular symptoms were assessed using the Visual Light Sensitivity Questionnaire (VLSQ-8; 8–40) and Ocular Surface Disease Index (OSDI; 0–100), with OSDI Question 1 addressing light sensitivity (OSDI-Q1; 0–4).</div></div><div><h3>Results</h3><div>COP patients exhibited lower VPDT than controls (log lux, 1.60 ± 1.17 vs. 2.42 ± 1.05; P = 0.006), indicating greater photosensitivity discomfort. No differences in VPDT were seen across COP subtypes. COP patients also reported greater symptom severity than controls, with higher VLSQ-8 (21.92 ± 1.41 vs. 9.03 ± 0.53), OSDI (50.84 ± 3.88 vs. 2.82 ± 0.85), and OSDI-Q1 (2.00 ± 0.24 vs. 0.14 ± 0.06) scores (all P < 0.001). VPDT negatively correlated with VLSQ-8 (ρ = −0.75) and OSDI-Q1 (ρ = −0.62), demonstrating alignment between subjective light sensitivity symptoms and OPA-measured photosensitivity discomfort. Multivariable regression identified fibromyalgia as the strongest predictor of VPDT (19.6 % variance explained), with chronic fatigue improving the model (26.5 %).</div></div><div><h3>Conclusion</h3><div>COP subjects display greater photosensitivity-related discomfort than controls, highlighting the OPA's potential as a psychophysical tool for quantifying photoallodynia. Further research is needed to assess its diagnostic utility across COP subtypes.</div></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 64-71"},"PeriodicalIF":5.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to “Methodological considerations regarding 'Ranking the efficacy of topical treatments for ocular allergy: A network meta-analysis of current evidence'” 对“对眼部过敏局部治疗的疗效排序的方法学考虑：对现有证据的网络荟萃分析”的回应

IF 5.6 1区医学 Q1 OPHTHALMOLOGY

Ocular Surface

Pub Date : 2025-10-01 Epub Date: 2025-10-29 DOI: 10.1016/j.jtos.2025.10.007

Luksanaporn Krungkraipetch , Taweelarp Tansavadi , Dechathorn Krungkraipetch

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Ocular Surface

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀